MELA Stock News 0.52 05/13/2014 15:24:48 Mela Sciences Inc (

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Mela Sciences Inc (MELA) 0.52 $MELA

MELA Sciences Reports Its First Quarter 2014 Business and Financial Results
Marketwire - 22 mins ago
MELA Sciences, Inc. (NASDAQ: MELA), developer of the MelaFind(R) system, an optical diagnostic device approved for use in the United States and the European Union to assist dermatologists in melanoma diagnosis, today announced results for its fiscal 2014 first quarter (Q1'14) ended March 31, 2014. MELA will host a conference call today at 4:30 pm EDT to review its results and recent progress.

MELA Sciences Predictive Probability Study Supports Increased Diagnostic Accuracy by Dermatologists for Melanoma
Marketwire - Thu May 08, 7:37AM CDT
MELA Sciences, Inc. (NASDAQ: MELA), developer of the MelaFind(R) system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, today announced statistically significant preliminary results of a study that measured the impact of predictive probability information (probability of lesion being melanoma and melanoma/high-grade) on dermatologists' decisions to biopsy ambiguous pigmented skin lesions.

Melanoma Diagnostic Developer, MELA Sciences, Hosts Q1 Conference Call Tuesday, May 13th at 4:30 pm ET
Marketwire - Wed May 07, 4:24PM CDT
MELA Sciences, Inc. (NASDAQ: MELA), developer of the MelaFind(R) system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, will release its first quarter 2014 financial results and provide an update on its activities on Tuesday, May 13, 2014, after the market's close. MELA Sciences President and CEO, Rose Crane, and the Company's CFO, Robert Cook, will host a conference call at 4:30pm ET that day to review the Company's progress and to answer questions.

MELA Sciences Secures Final Investigative Site and Enrolls 100+ Patients for Post-Approval Study for MelaFind(R) System Optical Melanoma Diagnostic Device
Business Wire - Wed Apr 30, 7:37AM CDT
MELA Sciences, Inc. (NASDAQ:MELA), developer of the MelaFind(R) system, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced that it has concluded an agreement with the sixth and final investigative site participating in the Company's post-approval study (PAS) of the MelaFind(R) system for the diagnosis of melanoma. More than 100 patients have been enrolled in the study to date.

Medical Diagnostic Developer MELA Sciences Appoints Senior Healthcare Finance Executive Robert W. Cook as CFO
Business Wire - Wed Apr 09, 7:23AM CDT
MELA Sciences, Inc. (NASDAQ:MELA), developer of the MelaFind(R) system, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, appointed veteran healthcare executive Robert W. Cook as Chief Financial Officer, filling the position which had been vacant since December 31, 2013. Mr. Cook brings over 20 years of experience in senior finance and management leadership roles in the healthcare and pharmaceutical industries, most recently as SVP and CFO of Immune Pharmaceuticals Inc. (NASDAQ OMX First North and OTCQX:IMNP), a developer of antibody therapeutics for cancer treatment, following its merger with EpiCept Corporation (Nasdaq OMX Stockholm and OTCQX:EPCT).

MELA Sciences Announces 2013 Fourth Quarter and Year-End Financial Results
Business Wire - Mon Mar 17, 3:00PM CDT
MELA Sciences, Inc. (NASDAQ:MELA), (the "Company", developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced financial results for the fourth quarter and year ended December 31, 2013.

MELA Sciences elects Samuel E. Navarro to board
M2 - Mon Mar 17, 5:16AM CDT
Optical diagnostic company MELA Sciences (NasdaqCM:MELA) revealed on Friday the addition of Samuel E. Navarro to its board of directors, increasing its members to eight.

Optical Diagnostic Developer, MELA Sciences, Appoints Veteran Medical Device Investment Banker, Samuel Navarro, as Director
Business Wire - Fri Mar 14, 6:55AM CDT
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today announced the appointment of veteran medical device investment banker Samuel E. Navarro to the Board of Directors. Mr. Navarro's appointment brings MELA's Board to eight members.

MELA Sciences, Inc. (MELA) Pioneering Earlier Detection of Melanoma Is Featured in Flaherty Financial News Newsletter #41
Marketwire - Tue Mar 11, 9:35AM CDT
Fine tuning the crusade by MELA Sciences, Inc. (NASDAQ: MELA) to identify deadly melanoma earlier is featured in the March 10, 2014 issue of Flaherty Financial News Newsletter. It follows up two previous articles written four years ago.

Dermatology Diagnostic Developer, MELA Sciences, to Host Q4 Conference Call Monday, March 17, 2014 at 4:30 pm ET
Business Wire - Thu Mar 06, 8:36AM CST
MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, will release its fourth quarter and full year 2013 results on Monday, March 17, 2014, after the market's close. MELA Sciences President and CEO, Rose Crane will host a conference call that day at 4:30pm ET to review the results and provide general business update.

Rose Crane, CEO of Melanoma Diagnostics Provider, MELA Sciences, to Be Interviewed Live Today on Clear Channel Business Talk Radio DFW1190AM
Marketwire - Tue Feb 25, 10:04AM CST
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, announced that its CEO Rose Crane will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network. All interested investors and prospective customers across the US are encouraged to tune in and listen live via Clear Channel's nationally syndicated iHeart Radio stream.

Melanoma Diagnostic Provider, MELA Sciences Receives 180-Day Extension to Meet NASDAQ Minimum Bid Price
Business Wire - Mon Feb 24, 6:55AM CST
MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, has filed a Form 8-K providing full details of a 180-day grace period it has received from NASDAQ to fulfill the minimum $1.00 bid price requirement. The extension gives the Company until August 18, 2014 to regain compliance.

MELA Sciences Completes Private Placement to Institutional Investors and MELA Sciences Directors
Business Wire - Wed Feb 05, 4:15PM CST
MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today announced the closing of its previously announced $12.45 million private placement of convertible preferred stock, common stock warrants and common stock. Net proceeds to the Company from this offering are approximately $11.5 million.

Kakamega Small-Scale Farmers Get Sh29m World Bank Boost
by Hilton Otenyo - All Africa Global Media - Tue Feb 04, 4:43AM CST
SMALL scale farmers in Kakamega county have received Sh29 million through a World Bank funded project to boost income and reduce poverty.

Melanoma Diagnostic Provider, MELA Sciences Provides Details of Recent $12.45 Million Private Placement
Business Wire - Mon Feb 03, 6:55AM CST
MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today filed a Form 8-K providing full details from its recent Private Placement. Following is the text of the details relating to the private placement that were provided in the Form 8-K.

CORRECTING and REPLACING Melanoma Diagnostic Provider, MELA Sciences, to Raise $12.45 Million in Private Placement to Institutional Investors and MELA Sciences Directors
Business Wire - Fri Jan 31, 1:03PM CST
Second graph, second sentence of release should read ...13,297,297 shares of common stock at an exercise price of $0.74. (sted ...11,714,286 shares of common stock at an exercise price of $0.74.).

Melanoma Diagnostic Provider, MELA Sciences, to Raise $12.45 Million in Private Placement to Institutional Investors and MELA Sciences Directors
Business Wire - Fri Jan 31, 8:44AM CST
MELA Sciences, Inc. (NASDAQ: MELA), (the Company) developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today announced it has entered into definitive agreements with institutional investors and management for the private placement of $12.45 million of the Company's convertible preferred stock, common stock warrants and common stock. The investors in the transaction were funds managed by Sabby Management, LLC, which comprise the Company's largest existing beneficial shareholder, and Broadfin Capital, LLC. In conjunction with the financing, MELA Sciences' directors have agreed to purchase $150,000 in restricted common stock priced at $0.74 per share, yesterday's closing bid price for MELA's common stock.

Dermatologist Highlights Medical Benefits of MelaFind Device in Aiding Melanoma Diagnosis at Most Treatable Stage
Business Wire - Thu Jan 30, 6:55AM CST
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, hosted a MelaFind(R) workshop during the 10th Annual Maui Derm Conference in Hawaii. The conference seeks to increase physicians' knowledge of developments in medical and cosmetic dermatology.

Medical Diagnostic Developer MELA Sciences to Present at SeeThruEquity Microcap Conf. Feb. 6 in NYC and to Exhibit at Maui Dermatology Conf. Jan. 26-30
Business Wire - Mon Jan 27, 6:55AM CST
MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced its CEO, Rose Crane, will present at the SeeThruEquity Winter Microcap Investor Conference on February 6, 2014 at 9:30 am ET in New York. Ms. Crane; Robert Coradini, Chairman; Mary Phellan, Controller; and Diana Garcia Redruello, head of the MelaFind Commercial Team will be available for one-on-one meetings that day.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 286

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 238

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 305

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 131

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 0

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 0

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Breakthroughs in Lung Cancer Treatment with Reqorsa

Updated Category News Views 182

Innovative Advances in Lung Cancer Treatment The fight against lung cancer continues to evolve, showcasing promising advancements that bring new hope to patients. Genprex, Inc. is at the forefront of this battle with its revolutionary gene therapy known as Reqorsa. This cutting-edge treatment has been developed specifically to target KRAS mutation in non-small cell lung...

Continue Reading
EfTEN United Property Fund Reports October Earnings and NAV

Updated Category News Views 192

Insights into EfTEN United Property Fund's Recent Performance EfTEN United Property Fund demonstrated a net profit of 110 thousand euros for October, totaling 2.214 million euros for the first ten months of the year, marking a significant improvement from 724 thousand euros during the same period last year. This impressive financial outcome led to a distribution to...

Continue Reading
Cardiff Oncology Reports Encouraging Results in mCRC Trial

Updated Category News Views 236

Cardiff Oncology Reveals Promising Clinical Trial Results Cardiff Oncology, Inc. (Nasdaq: CRDF), a pioneering clinical-stage biotechnology company, has recently announced encouraging results from its ongoing CRDF-004 clinical trial. This randomized Phase 2 trial is investigating the effects of onvansertib in patients suffering from first-line RAS-mutated metastatic...

Continue Reading
Japan's Growing Casting Polyurethane Market and Its Future

Updated Category News Views 127

Japan's Casting Polyurethane Market: A Rising Force The Japan casting polyurethane market is on the verge of significant transformation, anticipated to elevate from a valuation of US$ 134.74 million to a remarkable US$ 248.24 million by 2033. This growth trajectory highlights a compelling compound annual growth rate (CAGR) of 7.08%, revealing the underlying strength...

Continue Reading
Hudson Technologies Faces Challenges Amid Downgrade by B.Riley

Updated Category News Views 353

B.Riley Downgrades Hudson Technologies Stock In a recent market statement, B.Riley has lowered its outlook on Hudson Technologies (NASDAQ: HDSN), shifting the stock rating from Buy to Neutral. This adjustment comes amidst new growth projections adjusted downwards from +16.6% to +8.5%. The modification in expectations has been linked to ongoing pressures on...

Continue Reading